A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

PURPOSE: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotein, in patients with advanced cancers. MATERIALS AND METHODS: Patient...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Lee, Hyun Jung, Heo, Dae-Seog, Cho, Joo-Youn, Han, Sae-Won, Chang, Hye-Jung, Yi, Hyeon-Gyu, Kim, Tae-Eun, Lee, Se-Hoon, Oh, Do-Youn, Im, Seock-Ah, Jang, In-Jin, Bang, Yung-Jue
Materialtyp: Artigo
Språk:Inglês
Publicerad: Korean Cancer Association 2014
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4132447/
https://ncbi.nlm.nih.gov/pubmed/25038758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2014.46.3.234
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk